Clinical Trial Update: A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating imatinib (Gleevec) in patients with myelofibrosis and chronic myelomonocytic leukemia has completed. The study was sponsored by the Dan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myelomonocytic Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Myelofibrosis, Myeloid Metaplasia | Phase 2 | Status: COMPLETED